Leucine aminopeptidase

Leucine aminotranspeptidase is widely distributed in various tissues of the human body. It is most abundant in the liver, pancreas, gallbladder, small intestine, uterus and muscle, and is also distributed in the duodenum, serum and urine. Clinical determination of serum leucine aminotranspeptidase has a certain significance in the evaluation of the diagnosis and treatment of hepatobiliary diseases. Basic Information Specialist classification: Digestive examination classification: biochemical examination Applicable gender: whether men and women apply fasting: fasting Tips: Normal diet, psychological preparation for check-up. Normal value 1, dimethylaminobenzaldehyde colorimetric method 27 ~ 50u / L. 2, continuous monitoring method 11 ~ 30IU / L serum. Clinical significance Abnormal results This enzyme is widely distributed in various tissues of the human body, with the most content in the liver, pancreas, gallbladder, kidney, small intestine and myometrium. In pancreatic cancer, the activity of this enzyme is increased, and the positive rate is 100%. When the activity of the enzyme is normal, the pancreatic cancer can be negated, but the activity of the enzyme can also be increased in hepatobiliary diseases. Therefore, the clinical application value of this enzyme is similar to ALP, but the activity of this enzyme is normal in bone cancer. In addition, the activity of the enzyme gradually increased to 2 months after the normal pregnancy and decreased after delivery, and this should be noted when judging the results. Urine LAP activity is highest when toxic substances or diseases affect LAP-rich proximal tubules. Increased glomerular basement membrane permeability, renal tubular epithelial cell damage, drug-induced toxic renal damage, and increased LAP in renal tumors. Increased urinary LAP after tumor treatment suggests tumor recurrence. Analysis of various kidney cases revealed the highest positive rate of LAP. Need to check the diagnosis of liver and gallbladder disease in the population or the analysis of kidney disease damage. High results may be diseases: pancreatic cancer, elderly drug-induced liver disease considerations Inappropriate people: generally no special population. Taboo before the examination: normal diet, psychological preparation for the examination. Inspection process Dimethylaminobenzaldehyde colorimetry: 1. When the enzyme activity exceeds 400 u/L, the specimen is diluted and then measured. 2. The Km obtained by the method is 8.8×10-2 mmol/L, and the substrate concentration in the enzyme reaction solution of the method is 1.28 mmol/L, which is about 15 times of the Km value. Not suitable for the crowd no. Adverse reactions and risks no.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.